SANKEN (The Institute of Scientific and Industrial Research), Osaka University, Ibaraki, Osaka 567-0047, Japan.
Mol Pharm. 2022 Jul 4;19(7):2495-2505. doi: 10.1021/acs.molpharmaceut.2c00192. Epub 2022 May 20.
Cytoplasmic delivery of functional proteins into target cells remains challenging for many biological agents to exert their therapeutic effects. Extracellular vesicles (EVs) are expected to be a promising platform for protein delivery; however, efficient loading of proteins of interest (POIs) into EVs remains elusive. In this study, we utilized small compound-induced heterodimerization between FK506 binding protein (FKBP) and FKBP12-rapamycin-binding (FRB) domain to sort bioactive proteins into EVs using the FRB-FKBP system. When CD81, a typical EV marker protein, and POI were fused with FKBP and FRB, respectively, rapamycin induced the binding of these proteins through the FKBP-FRB interaction and recruited the POIs into EVs. The released EVs, displaying the virus-derived membrane fusion protein, delivered the POI cargo into recipient cells and their functionality in the recipient cells was confirmed. Furthermore, we demonstrated that CD81 could be replaced with other EV-enriched proteins, such as CD63 or HIV Gag. Thus, the FRB-FKBP system enables the delivery of functional proteins and paves the way for EV-based protein delivery platforms.
将功能性蛋白质递送到靶细胞的细胞质中仍然是许多生物制剂发挥治疗作用的挑战。细胞外囊泡(EVs)有望成为蛋白质递送的有前途的平台;然而,将感兴趣的蛋白质(POIs)有效加载到 EVs 中仍然难以实现。在这项研究中,我们利用小分子化合物诱导 FK506 结合蛋白(FKBP)和 FKBP12-雷帕霉素结合(FRB)结构域之间的异二聚化,使用 FRB-FKBP 系统将生物活性蛋白质分类到 EVs 中。当将典型的 EV 标记蛋白 CD81 和 POI 分别与 FKBP 和 FRB 融合时,雷帕霉素通过 FKBP-FRB 相互作用诱导这些蛋白质的结合,并将 POI 募集到 EVs 中。释放的 EV 展示了病毒衍生的膜融合蛋白,将 POI 货物递送到受体细胞,并确认了其在受体细胞中的功能。此外,我们证明 CD81 可以被其他富含 EV 的蛋白质替代,例如 CD63 或 HIV Gag。因此,FRB-FKBP 系统能够递送电活性蛋白质,并为基于 EV 的蛋白质递送平台铺平了道路。